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ARTICLE
Clinical Study
Long-term efficacy, tolerability and overall survival in patients
with platinum-sensitive, recurrent high-grade serous ovarian
cancer treated with maintenance olaparib capsules following
response to chemotherapy
Michael Friedlander1, Ursula Matulonis2, Charlie Gourley3, Andreas du Bois4, Ignace Vergote5, Gordon Rustin6, Clare Scott7,
Werner Meier8, Ronnie Shapira-Frommer9, Tamar Safra10,11, Daniela Matei12, Vadim Shirinkin13, Frédéric Selle14,15, Anitra Fielding16,19,
Elizabeth S. Lowe17, Emma L. McMurtry16, Stuart Spencer16, Philip Rowe16, Helen Mann16, David Parry16 and Jonathan Ledermann18
BACKGROUND: In Study 19, maintenance monotherapy with olaparib significantly prolonged progression-free survival vs placebo
in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer.
METHODS: Study 19 was a randomised, placebo-controlled, Phase II trial enrolling 265 patients who had received at least two
platinum-based chemotherapy regimens and were in complete or partial response to their most recent regimen. Patients were
randomised to olaparib (capsules; 400 mg bid) or placebo. We present long-term safety and final mature overall survival (OS; 79%
maturity) data, from the last data cut-off (9 May 2016).
RESULTS: Thirty-two patients (24%) received maintenance olaparib for over 2 years; 15 (11%) did so for over 6 years. No new
tolerability signals were identified with long-term treatment and adverse events were generally low grade. The incidence of
discontinuations due to adverse events was low (6%). An apparent OS advantage was observed with olaparib vs placebo (hazard
ratio 0.73, 95% confidence interval 0.55‒0.95, P= 0.02138) irrespective of BRCA1/2 mutation status, although the predefined
threshold for statistical significance was not met.
CONCLUSIONS: Study 19 showed a favourable final OS result irrespective of BRCA1/2 mutation status and unprecedented long-
term benefit with maintenance olaparib for a subset of platinum-sensitive, recurrent ovarian cancer patients.
British Journal of Cancer https://doi.org/10.1038/s41416-018-0271-y
INTRODUCTION
Ovarian cancer is the most common cause of gynaecological
cancer-related deaths and fifth leading cause of death from cancer
in women.1,2 Median overall survival (OS) for patients with
platinum-sensitive, recurrent ovarian cancer (defined as relapse ≥
6 months after platinum-based chemotherapy) is 2.5–3 years, and
patients typically receive a median of four lines of chemotherapy
after progression.3,4 Progression-free survival (PFS) for these
patients ranges from 8 to 13 months from the start of second-
line chemotherapy.3 In patients who respond to further platinum-
based chemotherapy, the median PFS from the end of treatment
is consistently 5–6 months5–7 and most patients are offered the
next line of palliative chemotherapy. Cumulative toxicities of
chemotherapy and the emergence of drug resistance limit
delivery and potential benefit of further treatment. Furthermore,
the duration of benefit associated with ‘salvage’ chemotherapy for
progression decreases with each subsequent line of treatment.8,9
There remains an unmet need for effective and well-tolerated
long-term maintenance treatment options for patients with
recurrent ovarian cancer to maintain quality of life and delay the
need for further chemotherapy, particularly after response.
Olaparib (Lynparza™), a poly(adenosine diphosphate–ribose)
polymerase (PARP) inhibitor, is approved (tablet formulation) for
treatment in the maintenance setting for patients with platinum-
sensitive relapsed ovarian cancer, irrespective of BRCA1/2 muta-
tion (BRCAm) status.10,11
We have previously reported data from Study 19
(NCT00753545), a Phase II trial that assessed the efficacy and
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safety of olaparib maintenance monotherapy in platinum-sensi-
tive, recurrent high-grade serous ovarian cancer patients, and
showed a significant improvement in PFS with maintenance
olaparib vs placebo (hazard ratio (HR) 0.35, 95% confidence
interval (CI) 0.25–0.49; P < 0.0001).5 The PFS prolongation was
durable, with 32 of 136 patients (24%) who received olaparib
being progression-free for >2 years.12 A pre-planned, retrospective
analysis of patients in Study 19 demonstrated that BRCAm patients
derived the greatest clinical benefit from olaparib (HR 0.18, 95% CI
0.10–0.31; P < 0.0001); however, a PFS advantage was also seen for
BRCA wild-type (BRCAwt) patients (HR 0.54, 95% CI 0.34–0.85; P=
0.0075).13 More recently, PFS data from the Phase III SOLO2 trial of
olaparib tablets as maintenance monotherapy in patients with
platinum-sensitive, relapsed ovarian cancer and a BRCAm con-
firmed a significant benefit for olaparib-treated patients compared
with those who received placebo (HR 0.30, 95% CI 0.22–0.41; P <
0.0001).6 Although the initial analysis of OS in Study 19 (data
maturity: 38%) did not detect a treatment effect, previously
reported updated data from an interim analysis (data cut-off
[DCO] 30 September 2015; data maturity: 77%) suggested an
advantage in OS for patients receiving olaparib vs placebo (HR
0.73, 95% CI 0.55–0.96; nominal P= 0.025).5,14
Safety data from clinical trials in recurrent ovarian cancer
patients have shown that olaparib (capsule) monotherapy is
generally well tolerated, and data from SOLO2 suggest the
new tablet formulation of olaparib has a similar tolerability
profile.6,14–18 Furthermore, there was no detriment to health-
related quality of life (HRQoL) while on treatment in either Study
19 or SOLO2.19,20 Given its clinical profile, long-term administra-
tion of olaparib as maintenance monotherapy in ovarian cancer
patients is feasible and an attractive option. Here, we report the
final protocol-defined OS analysis from Study 19, characterise
those patients who have derived long-term benefit from olaparib
and, in particular, assess the long-term safety and tolerability of
olaparib treatment.
MATERIALS AND METHODS
Study design and population
Study 19 was a Phase II, randomised, double-blind, placebo-
controlled trial (NCT00753545). Eligible patients were at least 18
years old, with recurrent ovarian, fallopian tube or primary
peritoneal cancer with high-grade serous histology and were
platinum sensitive. Patients had received two or more prior
courses of platinum-based chemotherapy and were in complete
or partial response to their most recent regimen (Supplemen-
tary Methods). Additional eligibility criteria have been described
previously.5 Known BRCAm status was not required but was
established retrospectively by germline or tumour testing for
patients with appropriate samples available who provided
consent (Supplementary Methods).
Treatments
Patients were randomised 1:1 to olaparib or matching placebo, as
described previously.5 Olaparib maintenance monotherapy (400
mg bid, capsule formulation) was administered orally and
treatment continued until disease progression, if toxicities were
manageable (Supplementary Methods).
Assessments
Tumour assessments were conducted every 12 weeks until week
60, and every 24 weeks thereafter, until objective disease
progression or withdrawal of consent. Response Evaluation
Criteria in Solid Tumours (RECIST) data were not collected after
the primary DCO (30 June 2010). The primary endpoint of the
study was PFS, for which data have been reported previously.5 OS
was a secondary endpoint and we report the final analysis for this
outcome here. Patients were monitored for OS with follow-up
every 12 weeks after treatment discontinuation. Exploratory
analyses of time to first and second subsequent therapy or death
(TFST, TSST) were also conducted. Safety and tolerability were
assessed throughout the study by recording adverse events (AEs;
graded using CTCAE v3.0), physical examination results, vital signs
and laboratory findings.
Statistical analyses
Study 19 was powered to ensure a sufficient number of PFS events
in the overall study population; it was not formally powered to
assess differences in OS, either between active treatment and
placebo or within different patient groups. Previous OS analyses
are listed in the Supplementary Methods. The final OS analysis for
Study 19, reported here, (79% data maturity; DCO: 9 May 2016;
two-sided α= 0.95%) was protocol defined and the analysis set for
OS included all patients randomised to treatment. The results
should be regarded as descriptive and P-values as nominal. OS,
TFST and TSST were analysed using an adjusted Cox proportional
hazards model (Supplementary Methods). Restricted means OS
analyses were carried out using the pseudovalues method
previously described.22
RESULTS
Study population
Of 265 patients randomised in Study 19, 136 were to olaparib and
129 to placebo (Fig. 1). BRCAm status was established for 254 of
265 patients (96%; 131 olaparib vs 123 placebo), including 97 for
whom BRCAm status was known at study entry; 136 patients were
classified as BRCAm (74 olaparib vs 62 placebo). At the final DCO (9
May 2016), 14 olaparib-arm patients (10%) and 1 placebo-arm
patient (1%) were continuing treatment.
Patient demographics and baseline characteristics were gen-
erally well balanced for the overall study population and the
BRCAm and BRCAwt subgroups.5,13 Patients treated with olaparib
for over 2 years had similar characteristics to the overall study
population (Table 1, Supplementary Table 1).
OS and subsequent anticancer therapy
The final DCO corresponded to 79% OS data maturity (210 deaths
from 265 patients), with a median follow-up of 78.0 months. An
apparent advantage in OS for patients randomised to olaparib
maintenance monotherapy vs placebo in the total study popula-
tion (HR 0.73, 95% CI 0.55‒0.95; nominal P= 0.02138; Fig. 2a) did
not meet the threshold defined for statistical significance (P <
0.0095). A separation in favour of olaparib treatment was seen in
the Kaplan–Meier (KM) curves for the overall study population,
BRCAm and BRCAwt subgroups as duration of follow-up increased
(Fig. 2). The separation of the KM curves became more apparent
after 36 months of follow-up, reflecting the long-term benefit
derived for olaparib-treated patients. These data are similar to
those reported from the previous DCO (30 September 2015).14
Although there was little difference in point estimate medians
(29.8 months olaparib vs 27.8 placebo), an exploratory restricted
means OS analysis indicated a difference in survival of 6.1 months
between treatment arms (95% CI −0.3‒12.6; 41.6 months olaparib
vs 35.5 placebo).
Although crossover between treatment arms was not permitted
in Study 19, 17 of 129 patients (13.2%) in the placebo group
subsequently received PARP inhibitors via other studies. We
therefore conducted an exploratory post-hoc OS analysis of 103
olaparib-arm and 92 placebo-arm patients by excluding patients
from sites where at least one patient had received subsequent
PARP inhibitor treatment. At the final DCO, this resulted in an
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adjusted OS HR of 0.68 (95% CI 0.49‒0.95; BRCAm see
Supplementary Results). With the exception of PARP inhibitor
treatment, types of subsequent therapy received were similar
across both treatment arms (Supplementary Table 2).
Times to first and second subsequent therapy or death
Exploratory analyses of TFST (87% data maturity, median follow-up
77.4 months) and TSST (85% data maturity, median follow-up
77.1 months) were performed at the final DCO (Supplementary
Figure 1). Median TFST and TSST were significantly longer in the
olaparib arm in the overall study population, BRCAm and BRCAwt
subgroups.
Long-term treatment exposure
At the final DCO (9 May 2016), 15 of 136 patients (11%)
had received maintenance olaparib monotherapy for 6 years or
more; eight of these had a BRCAm and seven were classified as
BRCAwt (Fig. 3), although one BRCAwt patient was subsequently
found to carry a somatic BRCAm following exploratory biomarker
testing.23
Twenty-two of 32 olaparib-arm patients (69%) and all five
placebo-arm patients who were on treatment for at least 2 years
were receiving the full treatment dose (400 mg bid) immediately
prior to discontinuation or the end of follow-up. Eight olaparib-
arm patients (25%) were at a reduced dose of 200mg bid, six of
whom had their dose reduced prior to 2 years, with the remaining
two (6%) receiving 100mg bid, one of whom had their dose
reduced prior to 2 years.
The main reason for discontinuation of study treatment was
disease progression (210 of 249 patients; Fig. 1 and Supplemen-
tary Figure 2). After 2 years on treatment, the rate of discontinua-
tion of olaparib decreased. Eighteen patients discontinued after
this time; nine due to disease progression, four voluntarily, three
due to AEs and two due to protocol non-compliance.
At the final DCO, in the full analysis set, mean (standard
deviation) compliance with study treatment (assessed using
capsule counts) was 96.9% (8.9) in the olaparib arm and 99.0%
(3.4) in the placebo arm.
AE profile
During Study 19, the most common AEs in the olaparib group
were early onset of nausea (71%), fatigue/asthenia (63%), vomiting
(35%) and diarrhoea (27%), consistent with those previously
reported. No new safety findings were observed in the overall
study population and safety findings for BRCAm patients were
similar to those in the overall population (Supplementary
Table 3).5,13,14 Exposure-adjusted AE rates are presented in the
Supplementary Results. Since the study began, serious AEs (SAEs)
reported in more than one patient in either treatment group were:
anaemia (3 olaparib vs 0 placebo), pancytopenia (2 olaparib
[patients subsequently developed myelodysplastic syndrome
(MDS) and acute myeloid leukaemia (AML), respectively] vs 0
placebo), constipation (2 olaparib vs 0 placebo), gastritis (0
olaparib vs 2 placebo), small intestinal obstruction (2 olaparib vs 3
placebo), fractured femur (2 olaparib vs 0 placebo) and dyspnoea
(2 olaparib vs 0 placebo).
326 patients enrolled
265 randomised patients
14 remained
in study
61 did not meet eligibility criteria
136 assigned to olaparib
136 received olaparib
129 assigned to placebo
128 received placebo
28 still in study at final data cut-off
14 remaining on randomised treatment
11 still in study at final data cut-off
1 remaining on randomised treatment
122 discontinued study treatment
8 adverse events
94 condition worsened
3 severe protocol non-compliance
1 lost to follow-up
14 voluntary discontinuation
2 other
108 discontinued study
98 died
2 lost to follow-up
7 voluntary discontinuation
1 protocol non-compliance
127 discontinued study treatment
2 adverse events
116 condition worsened
1 severe protocol non-compliance
8 voluntary discontinuation
10 remained
in study
117 discontinued study
 111 died*
 3 lost to follow-up
 3 voluntary discontinuation
Fig. 1 Patient disposition. *One patient was randomly assigned to the placebo group but withdrew consent and withdrew from the study
without receiving treatment. This patient subsequently died but is not included in the number of deaths for patients who discontinued the
study after being treated with placebo
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Since the last DCO (30 September 2015), three new SAEs were
reported in two patients in the olaparib group (non-cardiac chest
pain and aphasia in one patient, who had previously developed
brain lesions, and an incarcerated abdominal hernia in the other
patient).
A smaller proportion of olaparib-arm patients reported AEs late
in treatment (75%) compared with the full study duration (97%),
although the prevalence of pruritus, urinary tract infection,
dyspnoea and pain in extremity was increased (Table 2a). There
were no AEs for which >20% of patients experienced a new
episode after 2 years of treatment.
Of the 264 patients who received study treatment, 209 deaths
had occurred at the time of the final DCO (98 olaparib vs 111
placebo). In the investigators’ opinion, the vast majority of
patients in both treatment groups died because of progression
of their ovarian cancer (188 patients). Since the study began,
two patients, both in the olaparib arm and both with a BRCAm,
experienced AEs that resulted in death. One of these deaths had
occurred at the time of the last DCO; this patient died due to
AEs of haemorrhagic stroke and thrombocytopenia, deemed to
be treatment related.14 The other death was due to previously
reported AML; this AE occurred 14 days after discontinuation of
study treatment and the patient, who had received olaparib for
over 4 years, died approximately 1 year and 9 months later. This
patient previously was reported to have a SAE of pancytopenia
while on study treatment. This was the only case of AML
reported in Study 19; two patients were reported with MDS, as
described previously14 (see Supplementary Results). All three
patients had previously received two lines of platinum-based
chemotherapy. Four olaparib-treated patients developed new
primary malignancies: adenocarcinoma of the colon, ductal
carcinoma in situ, papillary thyroid cancer and squamous cell
carcinoma of the oral cavity (see Supplementary Results). Two
cases of pneumonitis were reported during the study, one in the
olaparib arm <3 months into treatment, and one in the placebo
arm, both of grade 1 severity.
Of those patients who received olaparib, throughout the whole
study 53 (39%) had dose interruptions (47 [35%] for AEs) and 59
(43%) had dose reductions (35 [26%] for AEs). In the placebo arm, 23
patients (18%) had dose interruptions (13 [10%] for AEs) and 29
patients (23%) had dose reductions (5 [4%] for AEs; BRCAm see
Supplementary Results). Since the last DCO, no new AEs have led to
discontinuation of study treatment.14 Overall, AEs leading to
discontinuation of study treatment were reported for eight (6%)
olaparib-arm and two (2%) placebo-arm patients (see Supplemen-
tary Results); no single AE was the reason for discontinuation of more
than one patient in either treatment arm. All AEs leading to
treatment discontinuation were considered related to study treat-
ment in the investigator’s opinion, and have been previously
reported.5,13,14
Table 1 Patient demographics and baseline characteristics
All patients (n= 265) Patients on treatment ≥ 2 years
(n= 37)
Olaparib (n= 136) Placebo (n= 129) Olaparib (n= 32) Placebo (n= 5)
Age (years) 58.0 (21‒89) 59.0 (33‒84) 60.0 (43‒80) 59.0 (48‒71)
Ancestrya
Non-Jewish 115 (85) 112 (87) 26 (81) 5 (100)
Jewish 21 (15) 17 (13) 6 (19) 0
Number of previous lines of chemotherapy
2 59 (43) 63 (49) 14 (44) 3 (60)
3 43 (32) 34 (26) 11 (34) 2 (40)
4 18 (13) 19 (15) 4 (13) 0
≥5 16 (12) 13 (10) 3 (9) 0
Primary tumour location
Ovary 119 (88) 109 (84) 28 (88) 5 (100)
Fallopian tube or primary peritoneal 17 (13) 20 (16) 4 (13) 0
Time to progression after completion of penultimate platinum-based
regimen
>6 to ≤ 12 months 53 (39) 54 (42) 11 (34) 1 (20)
>12 months 83 (61) 75 (58) 21 (66) 4 (80)
Objective response to most recent platinum-based regimen
Complete response 57 (42) 63 (49) 18 (56) 4 (80)
Partial response 79 (58) 66 (51) 14 (44) 1 (20)
Secondary debulking ≤ 1 month prior to randomisation 22 (16) 13 (10) 8 (25) 0
Metastatic disease at baseline
Any site 55 (40) 49 (38) 10 (32) 2 (40)
Lymph nodes 26 (19) 10 (8) 4 (13) 1 (20)
Peritoneum 20 (15) 11 (9) 2 (6) 1 (20)
Hepaticb 19 (14) 12 (9) 5 (16) 0
Data are median (range) or n (%). Some of these baseline data have been previously reported5,14
aAncestry was self-reported
bIncluding gall bladder
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Placebo
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Deaths/total patients (%)
Median OS, months (95% CI)
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Fig. 2 Overall survival in all patients and according to BRCA mutation status: a overall study population; b BRCAm subgroup; c BRCAwt
subgroup
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Characterisation of common AEs
We further characterised the common AEs of nausea, vomiting,
fatigue/asthenia and anaemia in Study 19 by determining their
severity and outcome (Table 2b). These events were generally low
grade, did not require treatment modification, and only two
patients (one per treatment arm) discontinued treatment due to
common AEs. Anaemia was the most common haematological
toxicity, occurring in 23 and 7% of olaparib- and placebo-treated
patients, respectively. At study entry, 20 patients (15%) in the
olaparib arm had anaemia vs 14 (11%) in the placebo arm and 18
olaparib-treated patients (13%) received a blood transfusion
during the trial, (1 [1%] placebo). Data for BRCAm patients were
consistent with those for the overall population (Supplementary
Tables 5 and 6).
Patients who experienced common AEs typically did so for the
first time within a few months of the start of treatment and it was
rare for common AEs to initially develop after >6 months on
olaparib (event rates < 0.3 per patient year; Fig. 4, Supplementary
Figure 3 [BRCAm patients]). Prevalence plots for the common AEs
show the proportion of patients at risk (receiving treatment or
within their 30 day follow-up period) who experienced each AE
during a specific month. This is irrespective of AE start date, so AEs
with a long duration are represented over multiple months; note
that when there are only a few patients on treatment the
proportion experiencing an AE can appear to be high (Fig. 4,
Supplementary Figure 4 [BRCAm patients]).
DISCUSSION
We report the final analyses of long-term efficacy and tolerability
data from Study 19, a Phase II trial assessing olaparib maintenance
monotherapy (400 mg bid, capsule formulation) in patients with
platinum-sensitive, recurrent high-grade serous ovarian cancer in
response to their most recent platinum-based chemotherapy
regimen, representing the longest follow-up from any PARP
inhibitor trial reported. Our findings suggest an OS advantage for
patients receiving maintenance olaparib vs placebo, an effect not
yet observed for any chemotherapy regimen or other main-
tenance therapies in the recurrent ovarian cancer setting.3,24 It
should be noted that although Study 19 was not designed or
powered to show a statistically significant difference in OS, this OS
advantage with olaparib is consistent with previously published
analyses.5,13,14
The apparent OS benefit seen with olaparib appears to be
driven by long-term responders, with a separation in KM survival
curves between treatment arms seen after approximately 3
years.5,13 This is supported by an exploratory restricted means
OS analysis, carried out to assess average life-expectancy over the
whole survival curve, taking into account differences in hazard
ratio over time. Although consistent with previously reported data
showing that BRCAm patients had the greatest PFS benefit from
olaparib,13 these long-term OS results indicate that a subset of
patients within the BRCAwt group also experience durable long-
term benefit from maintenance olaparib monotherapy. It is likely
that these patients have homologous recombination repair (HRR)
deficiencies (germline or somatic) resulting in synthetic lethality
with exposure to olaparib. Approximately 50% of patients with
high-grade serous ovarian cancer are thought to have a deficiency
in HRR, opening up maintenance therapy for a significant number
of women with recurrent ovarian cancer.25 The challenge is to
identify which BRCAwt patients are most likely to benefit from a
PARP inhibitor. It has been recently reported that a positive
homologous recombination deficiency (HRD) score was associated
with long-term response ( > 2 years) to olaparib.12 Additionally, a
biomarker analysis of patients in Study 19 who remained on
treatment for ≥ 6 years has shown at least 5 of 15 patients were
classified as BRCAwt. This BRCAwt group included patients with
other HRR pathway gene mutations or a positive HRD score, as
well as a patient with no positive candidate predictive biomarker
test results.23 Other baseline characteristics were broadly similar
between the full study population and those on long-term
treatment, although an increased proportion of patients on
olaparib for at least 2 years had undergone secondary debulking
surgery shortly prior to randomisation in Study 19. The long-term
survivors in this study represent a highly selected subpopulation.
Although it is likely that factors such as patient heterogeneity and
the number of subsequent lines of treatment following progres-
sion may have contributed to the OS of patients, it should be
noted that in this randomised trial, 15 (11%) patients were on
olaparib for > 6 years, compared with only one (0.8%) placebo
recipient. It remains to be established why these patients achieved
such a durable response to olaparib.
Following progression, OS may be influenced by subsequent
therapy with platinum agents, bevacizumab and/or PARP inhibi-
tors. Crossover was not permitted in our study; however, 13% of
placebo-arm patients subsequently received a PARP inhibitor via
other clinical trials. This could have caused confounding of the OS
data and, consistent with this, we show an improved OS HR for
olaparib vs placebo when excluding patients from sites where at
least one patient received subsequent treatment with a PARP
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Table 2 AEs in Study 19: (a) episodes of any grade occurring after ≥ 2 years on treatment in > 7% of olaparib-arm patients in the overall population or
BRCAm subgroup; (b) severity and impact of common AEs on treatment since the start of Study 19
(a) Overall population BRCAm patients
Patients on treatment ≥2 years, n (%), preferred term Olaparib, n = 32 Placebo,
n = 5
Olaparib, n = 21 Placebo, n = 5
Patients with any AE occurring after 2 years on treatment 24 (75) 4 (80) 16 (76) 4 (80)
Fatigue/asthenia 6 (19) 0 4 (19) 0
Constipation 5 (16) 0 4 (19) 0
Pruritus 5 (16) 0 4 (19) 0
Urinary tract infection 5 (16) 0 4 (19) 0
Dizziness 5 (16) 0 3 (14) 0
Dyspnoea 5 (16) 0 3 (14) 0
Nausea 4 (13) 0 3 (14) 0
Abdominal distension 4 (13) 0 3 (14) 0
Back pain 4 (13) 0 3 (14) 0
Upper respiratory tract infection 4 (13) 0 3 (14) 0
Cough 4 (13) 0 2 (10) 0
Pain in extremity 4 (13) 0 2 (10) 0
Anaemiaa 3 (9) 0 3 (14) 0
Bone pain 3 (9) 0 3 (14) 0
Headache 3 (9) 1 (20) 2 (10) 1 (20)
Peripheral swelling 3 (9) 0 2 (10) 0
Blood creatinine increased 3 (9) 0 1 (5) 0
Diarrhoea 3 (9) 0 1 (5) 0
Sinusitis 3 (9) 0 1 (5) 0
Vomiting 3 (9) 0 1 (5) 0
Abdominal pain 2 (6) 1 (20) 2 (10) 1 (20)
Alopecia 2 (6) 0 2 (10) 0
Cystitis 2 (6) 0 2 (10) 0
Ecchymosis 2 (6) 0 2 (10) 0
Osteoarthritis 2 (6) 0 2 (10) 0
Pancytopenia 2 (6) 0 2 (10) 0
Pyrexia 2 (6) 0 2 (10) 0
Sensory disturbance 2 (6) 0 2 (10) 0
Sleep disorder 2 (6) 0 2 (10) 0
(b) Nausea Vomiting Fatigue/asthenia Anaemiaa
Olaparib Placebo Olaparib Placebo Olaparib Placebo Olaparib Placebo
n 136 128 136 128 136 128 136 128
Patients with AEs 96 (71) 46 (36) 48 (35) 18 (14) 86 (63) 59 (46) 31 (23) 9 (7)
Patients whose first incidence occurred after >6 months on
treatment
12 (9) 4 (3) 11 (8) 4 (3) 18 (13) 4 (3) 10 (7) 0
Total episodesb 129 58 92 20 118 72 40 10
Grade 1 102 (79) 46 (79) 66 (72) 12 (60) 69 (58) 58 (81) 5 (13) 6 (60)
Grade 2 24 (19) 12 (21) 23 (25) 7 (35) 37 (31) 10 (14) 24 (60) 3 (30)
Grade 3 or 4 3 (2) 0 3 (3) 1 (5) 12 (10) 4 (6) 11 (28) 1 (10)
Treatment interrupted 9 (7) 1 (2) 18 (20) 1 (5) 8 (7) 2 (3) 4 (10) 0
Treatment dose reduced 5 (4) 0 4 (4) 1 (5) 9 (8) 1 (1) 8 (20) 1 (10)
Treatment discontinued 1 (1) 1 (2) 0 0 0 0 0 0
AE resolved 105 (81) 46 (79) 90 (98) 17 (85) 73 (62) 35 (49) 28 (70) 7 (70)
Treatment required 56 (43) 10 (17) 21 (23) 3 (15) 5 (4) 3 (4) 30 (75) 2 (20)
Median time to onset of first event, days 4.0 13.0 52.0 64.5 28.0 29.0 29.0 92.0
Median duration of first event, months 2.7 0.8 0.1 0.1 3.0 3.3 2.8 0.5
Arbitrary cut-off corresponding to three or more patients in the overall population, or two or more patients in the BRCAm subgroup
All AEs reported after 2 years of treatment are included irrespective of whether this was the first incidence of a specific AE; incidences that began before 2
years, but that continued past 2 years on treatment are not included; no AEs were reported after 2 years by more than one patient in the placebo arm
AE adverse event
aIncludes patients with anaemia, haemoglobin decreased, red blood cell count decreased and haematocrit decreased
bPatients could experience more than one episode of the AE
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inhibitor, confirming similar findings from an earlier interim
analysis.26 This approach, excluding sites, was preferred to a
similar method excluding just crossover patients as it was felt to
lessen the potential confounding of removing only well-
performing placebo patients and better retain the benefits of
randomisation. As PARP inhibitors become more commonly
utilised and widely available, the feasibility of showing a
statistically significant OS benefit is decreasing; no future trials
will be able to have as little crossover as Study 19 and, given the
results of this and other maintenance studies with PARP inhibitors,
placebo-controlled trials would no longer be ethical in this
population.
Exploratory data for TFST and TSST reported here show
significant benefits with maintenance olaparib monotherapy
compared with placebo for the overall population and for the
BRCAm and BRCAwt subgroups, consistent with previous ana-
lyses.13,14 A clear separation between the olaparib and placebo KM
survival curves can be seen extending past 6 years of follow-up.
Since no tumour assessments were carried out in Study 19 after
the primary DCO (30 June 2010), TFST represents a reasonable
long-term surrogate for PFS, which was analysed with a median of
5.6 months’ follow-up. TFST and TSST data are consistent with the
observed advantage in PFS and OS for olaparib-arm patients and
show a clinically meaningful increase in time between chemother-
apy regimens, while also suggesting an extended efficacy benefit
with olaparib persisting beyond the next line of therapy.27
The long-term exposure seen in Study 19 is unprecedented for
a PARP inhibitor; consistently across BRCAm and BRCAwt
subgroups, 10% of patients experienced a durable benefit from
olaparib maintenance monotherapy for over 6 years. Almost 25%
of patients received olaparib for at least 2 years (compared with
4% of placebo-arm patients), considerably longer than the
expected median PFS of 4–6 months in this population.5–7 A
higher proportion of patients who received olaparib long term
had at least three prior lines of chemotherapy compared with
those who received placebo. The rate of discontinuation of
olaparib for any reason decreased after 2 years, suggesting
patients who reach this milestone are likely to receive continued
benefit from maintenance olaparib. It should be noted that
patients continued treatment long-term despite taking 16 large
capsules per day; a more patient-friendly formulation of olaparib,
requiring only 4 tablets per day, is now available.10,11
No new safety signals were identified since the previous
analysis and data reported here indicate that the tolerability
profile of olaparib is compatible with long-term treatment. Very
few patients discontinued treatment due to AEs in Study 19; 6 and
2% in the olaparib and placebo arms, respectively. The majority of
patients receiving olaparib long term were on full dose
immediately prior to the end of treatment, which suggests
enduring dose modifications are not required to maintain long-
term tolerability.
AEs of MDS and AML were rare in Study 19 and were reported
in both treatment arms. The incidence in Study 19 was broadly
consistent with that seen in SOLO2.6 The MDS, AML and new
primary malignancy AEs that occurred in Study 19 were unrelated
to duration of exposure to olaparib.
In line with previously published olaparib data,16–18 the most
common AEs in Study 19 were low-grade nausea, fatigue/asthenia
and vomiting, with anaemia the most common haematological
AE. These AEs usually occurred early and rarely first developed
after >6 months on olaparib or placebo. Only one patient
discontinued olaparib due to one of these common AEs (nausea).
Prevalence data show that the proportion of patients who
experienced vomiting or anaemia during any specific month
was low. More patients at a given time experienced nausea and
fatigue/asthenia, however, there was no increase in prevalence of
these AEs with long-term treatment. Due to the increased length
of time that patients spent on olaparib compared with placebo, it
is expected that more AEs will be observed in the olaparib arm.
Exposure-adjusted AE data (Supplementary Table 4), which show
the number of AEs per year on treatment, demonstrate more
limited differences between the two treatment groups for the
common AEs and show a higher rate of fatigue/asthenia in the
placebo arm; this suggests that the prevalence of this AE is similar
irrespective of treatment arm, and that fatigue/asthenia may not
be caused by olaparib.
These safety data should be considered in the context of
toxicity profiles associated with palliative chemotherapy, which is
commonly prescribed to patients at disease progression. There are
many potential adverse effects (AEs) associated with chemother-
apy, which can be cumulative, limiting the length of time patients
can remain on treatment.8 Currently, the reporting of AEs with
PARP inhibitors is based on an approach developed for AEs
associated with chemotherapy and arguably, new methods of AE
reporting, including patient reported AEs, may be more appro-
priate for characterising the intermittent AEs typically observed
with PARP inhibitors. In this study, intermittent AEs could have
been reported differently by individual investigators, either as a
single event of long duration or multiple events of short duration.
This inconsistency may have resulted in higher prevalence being
observed for events such as nausea, and fatigue/asthenia that had
a long median duration (and may have been intermittent during
this time). The generally low-grade, non-cumulative nature of the
common AEs observed with olaparib in Study 19 supports the
approach that they can be routinely managed by physicians
through dose modifications when required and symptomatic
treatment with standard procedures, such as antiemetics or
occasional blood transfusions, although regular haematological
monitoring is recommended for patients receiving olaparib.10,11,28
Various factors should be considered when weighing the value
of long-term maintenance therapy with a PARP inhibitor against
platinum-based chemotherapy alone followed by further lines of
treatment for recurrent disease at symptomatic progression.
Maintenance olaparib may not be effective in all patients, and is
often associated with low-grade intermittent toxicity that can
usually be controlled with simple supportive measures. However,
its efficacy and generally favourable long-term tolerability profile,
coupled with previously reported data showing no detrimental
impact on patients’ HRQoL during treatment,19 makes olaparib a
viable maintenance treatment option following response to
platinum-based chemotherapy, which should be discussed with
patients. Maintenance therapy with olaparib capsules prolonged
PFS in Study 19,5 and results from the ongoing Phase III SOLO2
trial of maintenance therapy with the tablet formulation of
olaparib also showed a significant increase in median PFS for
BRCAm patients, compared with placebo.6 Long-term follow-up
from SOLO2 and other ongoing trials will help further elucidate
the efficacy and tolerability profiles of olaparib maintenance
monotherapy and ultimately identify those patients with ovarian
cancer most likely to receive long-term benefit from maintenance
therapy with olaparib.
In addition, patient preference data showing the trade-off that
women with recurrent ovarian cancer who are receiving main-
tenance PARP inhibitor therapy are willing to make in terms of
gains in PFS and OS vs avoiding toxicity are also needed. Survey
results indicate that most women with recurrent ovarian cancer
required an increase in PFS of at least 5 months to make treatment
worthwhile,29 and patient preference data suggest that women
with recurrent ovarian cancer would accept a shorter PFS in order
to avoid severe adverse effects associated with chemotherapy
(e.g., nausea, vomiting).30 A delay in the time to subsequent
chemotherapy is also likely to be of importance to patients, with
TFST and TSST significantly prolonged with olaparib vs placebo in
both Study 19 and SOLO2.6
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CONCLUSIONS
The final analysis from Study 19 is the largest long-term survival
follow-up data for a PARP inhibitor and suggests an OS advantage
with olaparib maintenance monotherapy for patients with
platinum-sensitive, recurrent high-grade serous ovarian cancer.
Although the threshold for statistical significance was not met, a
numerical OS advantage was seen, irrespective of BRCAm status,
despite considerable crossover. This finding is supported by
significant improvements in PFS, TFST and TSST with maintenance
olaparib compared with placebo in BRCAm or BRCAwt women.
Almost 25% of patients in Study 19 received olaparib for at least 2
years and over 10% continued on treatment for 6 years or more,
demonstrating a prolonged, clinically meaningful benefit derived
from olaparib maintenance therapy, which is unprecedented in
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patients with recurrent ovarian cancer. The capsule formulation of
olaparib was well tolerated in Study 19; the majority of AEs in both
the overall population and BRCAm subgroup were low grade and
manageable with dose modifications or simple supportive
treatments and no new tolerability signals were identified with
long-term treatment. Taken together, these data support the use
of olaparib maintenance monotherapy as long-term treatment for
patients with platinum-sensitive, recurrent high-grade serous
ovarian cancer with or without a BRCAm.
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